Infectious Disease

USPSTF Confirms Recommendations for Chlamydia and Gonorrhea Screening Amid Record STI Cases

September 14, 2021

Read for 2 minutes

Source / information

Disclosure:
Dionne-Odom reports that she has received grants from the NIH / National Institute of Child Health and Human Development Funding. Kubik and Marrazzo do not report any relevant financial information. Please refer to the evidence review and letter of recommendation for all relevant financial information from the other authors.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

The U.S. Preventive Services Task Force announced today that it is recommending chlamydia and gonorrhea screening for all sexually active women under the age of 24 and women 25 and over who are at increased risk of infection.

According to the task force, there was insufficient evidence to make similar screening recommendations for men.

The B-level recommendations for screening in women and I-level recommendations for men mirror the 2014 USPSTF recommendations in this area, the task force said, and come amid an increase in cases. The CDC data released in April showed that 2019 was the sixth straight year that a record number of STIs were reported in the United States.

The recommendations are based on 27 studies with 179,515 participants, researchers wrote in JAMA. The review included four randomized trials examining the effectiveness of chlamydia screening. Marti Cubic, PhD, RN, a task force member and professor in the School of Nursing at the College of Health and Human Services at George Mason University, said Healio Primary Care.

Three of these had been reviewed in the previous Task Force recommendation. The new data from a large study involving over 63,000 participants was generally consistent with results from previous studies, and overall research showed that screening reduced the risk of serious health complications such as pelvic inflammation, “Kubik continued.

In a related editorial Jeanne Marrazzo, MD, MPH, and Jodie Dionne-Odom, MD, MSPH, Both of the Department of Infectious Diseases at the University of Alabama Medical School in Birmingham wrote that the USPSTF recommendations were “timely” but also “leave several questions unanswered”.

“It may be time to consider adding a more diverse menu of biologically-based evaluations of upper reproductive tract infections that incorporate comprehensive measures of infection and pathogenesis into consideration for screening effectiveness,” they wrote.

They also added that “the lack of new information on gonorrhea screening” and the only “high quality” randomized clinical trial on chlamydia screening “marked the need to invest in STI clinical trials to measure the effectiveness and effectiveness of screening Highlight with the help of clinical tests ”. relevant and precisely defined results for important population groups at risk of infection. ”

“Current guidelines targeting men (such as the USPSTF) should take into account the risk of STIs arising from sex as a man, be it with men, women, or both,” continued Marrazzo and Dionne-Odom.

Kubik acknowledged that there is a plethora of other research on STIs.

“We specifically call for more research into the pros and cons of screening men for chlamydia and gonorrhea,” she said. “We hope for further research into the pros and cons of screening men who have sex with men, members of the LGBTQ + community, and people whose gender is not binary.”

According to Kubik, the USPSTF will update the new recommendation “as needed”.

“We strive to keep all recommendations up to date and to revise the topics every 5 years depending on the available evidence,” she said. “In the meantime, we encourage clinicians to confidentially, respectfully, and culturally appropriate interview their patients about their sexual health and any concerns they may have about sexually transmitted infections.”

References:

Kantor A et al. JAMA. 2021; doi: 10.1001 / 2021.10577.

Marrazzo J, Dionne-Odom J. JAMA. 2021; 326 (10): 913-915.

USPSTF. JAMA. 2021; doi: 10.1001 / jama.2021.14081.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

Related Articles